Delivery Order SPE2DB22D3016-SPE2DB24FAUF1
Award Date
5/1/24
Potential Completion Date
5/2/24
Potential Value
$2.4K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Department of Defense's Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML pharmaceutical products. The delivery order, valued at $2,365.92, has a completion date of February 23, 2024. AmerisourceBergen Drug Corp is the prime contractor on an indefinite delivery contract (IDC) awarded by DLA, valued up to $999,999,999.00 with a...
Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, has been awarded a $7,886.40 firm fixed price delivery order contract by the Defense Logistics Agency (DLA) to provide HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product, with a completion date of February 12, 2024. This delivery order is part of an indefinite delivery contract (IDC) valued at up to $999,999,999.00 awarded to Amerisourcebergen Drug Corp by DLA, which serves as the primary vehicle for the...
The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical distributor Amerisourcebergen Corporation, to provide the HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML pharmaceutical product. The $3,943.20 award has a completion date of February 6, 2024. Amerisourcebergen Drug Corp, a for-profit organization, serves as a prime contractor to DLA Troop Support Medical, supplying pharmaceuticals and medical supplies in...
This federal contract award to Amerisourcebergen Drug Corp's Corporate Office division is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product. The contract is a Delivery Order issued by the Defense Logistics Agency (DLA), a defense agency, with a Ceiling Value of $1,971.60 and a completion date of June 6, 2024. This is a Firm Fixed Price contract. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up...
This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The Firm Fixed Price Delivery Order, valued at $1,182.96, has a period of performance through June 20, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999.00 through December 31, 2025, which serves as...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of the global pharmaceutical distribution company AmerisourceBergen Corporation. The contract, valued at $3,595.57, is for the provision of the HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML vaccine. The delivery order falls under a larger indefinite delivery contract (IDC) awarded by DLA to AmerisourceBergen Drug Corp, valued at up to $999,999,999.00 through December 31,...
This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the leading global pharmaceutical distributor Amerisourcebergen Corporation. The $27,996.72 contract is for the supply of the pharmaceutical product HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, with a completion date of March 4, 2024. Amerisourcebergen Drug Corp, a for-profit organization, serves as a prime contractor providing a wide range of pharmaceutical products...
This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product. The contract, valued at $19,716.00, is a Firm Fixed Price Delivery Order awarded by the Defense Logistics Agency (DLA). Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999.00 through December 31, 2025. This single-award IDC serves as the primary...
The U.S. Department of Defense's Defense Logistics Agency (DLA) Troop Support Medical awarded a delivery order contract valued at $2,760.24 to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of the HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML vaccine. This order is part of Amerisourcebergen's larger $999,999,999.00 Indefinite Delivery Contract with DLA Troop Support Medical to provide a comprehensive range of pharmaceutical products and medical supplies to support the...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML. The firm-fixed-price contract has a ceiling value of $1,577.28 and a period of performance through September 6, 2024. This award is not associated with a set-aside program. AmerisourceBergen has been awarded multiple indefinite delivery contracts (IDCs) by the DLA and other federal agencies, valued up to...